Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $29.00.

Several research analysts recently issued reports on the stock. Needham & Company LLC set a $25.00 target price on shares of Kyverna Therapeutics in a research note on Friday, September 25th. Benchmark reaffirmed a “buy” rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. HC Wainwright reiterated a “buy” rating on shares of Kyverna Therapeutics in a report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. Finally, William Blair upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd.

Institutional Investors Weigh In On Kyverna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new stake in shares of Kyverna Therapeutics in the 2nd quarter worth about $155,000. IFP Advisors Inc acquired a new position in Kyverna Therapeutics during the 2nd quarter valued at about $111,000. Spark Investment Management LLC bought a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $224,000. Allianz Asset Management GmbH bought a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $98,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Kyverna Therapeutics in the second quarter worth approximately $404,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Trading Up 0.2%

Shares of KYTX stock opened at $6.17 on Friday. Kyverna Therapeutics has a fifty-two week low of $5.93 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. The stock has a 50 day simple moving average of $7.65 and a two-hundred day simple moving average of $8.28. The company has a market cap of $381.55 million, a P/E ratio of -2.10 and a beta of 2.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05. Research analysts forecast that Kyverna Therapeutics will post -2.7 earnings per share for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for severe autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain cancers, to conditions in which abnormal B cells contribute to disease.

Kyverna’s lead product candidate, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells and potentially reset dysfunctional immune responses.